STRO vs TFX · rev $62.0M vs P/E 2083, rev $3.05B
Sutro Biopharma (STRO) versus Teleflex Incorporated (TFX) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Teleflex Incorporated (TFX) is a medical instruments & supplies company listed on NYSE.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported TFX revenue for 2024-12-31 was $3.05B. Net income was $69.7M. Revenue was up 2.4% from 2023-12-31 to 2024-12-31. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
STRO currently screens at market cap $470.8M. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
Not investment advice. Open the STRO and TFX stock pages for the full models.
Not investment advice.